Publications

Research

Virogin Poster at 3rd Annual mRNA-Based Therapeutics Summit Europe, Jan 2024






See more

HER2-expressing Oncolytic Herpes Simplex Virus Induces Robust and Persistent Immune Response Against HER2-Positive Tumor Cells.

Zahid Delwar, Olga Tatsiy, Dmitry V. Chouljenko, I-Fang Lee, Guoyu Liu, Xiaohu Liu, Luke Bu, Jun Ding, Manu Singh, Yanal M Murad, William Wei-Guo Jia * (2023).

See more

Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1.

Chouljenko, D. v., Murad, Y. M., Lee, I.-F., Delwar, Z., Ding, J., Liu, G., Liu, X., Bu, X., Sun, Y., Samudio, I., & Jia, W. W.-G. (2023).

See more

Novel mRNA vaccines encoding Monkeypox virus M1R and A35R protect mice from a lethal virus challenge. BioRxiv.

Hou, F., Zhang, Y., Liu, X., Murad, Y., Xu, J., Yu, Z., Hua, X., Song, Y., Ding, J., Huang, H., Zhao, R., Jia, W., & Yang, X. (2022).

See more

Pre-Existing HSV-1 Immunity Enhances Anticancer Efficacy of a Novel Immune-Stimulating Oncolytic Virus.

Ding, J., Murad, Y. M., Sun, Y., Lee, I. F., Samudio, I., Liu, X., Jia, W. W. G., & Zhao, R. (2022).

See more

Abstract 1913: Pre-existing HSV-1 Immunity enhances anti-cancer efficacy of a novel immune stimulating oncolytic virus - VG161.

Ding, J., Sun, J., Murad, Y., Lee, E., Samudio, I., Jia, W., & Zhao, R. (2021).

See more

Induction of durable antitumor response by a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes.

Chouljenko, D. v., Ding, J., Lee, I. F., Murad, Y. M., Bu, X., Liu, G., Delwar, Z., Sun, Y., Yu, S., Samudio, I., Zhao, R., & Jia, W. W. G. (2020).

See more

MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.

Lee, C. Y. F., Rennie, P. S., & Jia, W. W. G. (2009).

See more

Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1.

Jia, W. W. G., Mcdermott, M., Goldie, J., Cynader, M., Tan, J., & Tufaro, F. (1994).

See more

Clinical

The initial report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors.

Fu, S., Kundranda, M. N., Rahimian, S., Shen, Y., Tan, Q., Zhao, R., Esmaeili, N., Singh, M., Ding, J., Murad, Y., & Liang, T. (2023).

See more

Combination of novel oncolytic herpesvirus with paclitaxel as an efficient strategy for breast cancer therapy.

Deng, X., Shen, Y., Yi, M., Zhang, C., Zhao, B., Zhong, G., WeiyangLou, Xue, D., Leng, Q., Ding, J., Zhao, R., Jia, W., Dong, C., & Dai, Z. (2023).

See more

VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes.

Shen, Y., Song, W., Lin, D., Zhang, X., Wang, M., Li, Y., Yang, Z., Guo, S., Wang, Z., Sheng, J., Murad, Y., Ding, J., Lou, Y., Pan, X., Wu, Z., Zhao, R., Jia, W., Bai, X., & Liang, T. (2023).

See more